Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer

Zheng Jin; Fei Peng; Chao Zhang; Shuang Tao; Damo Xu; Zhenhua Zhu

doi:10.1016/j.heliyon.2023.e13195

Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer

Heliyon. 2023 Jan 25;9(2):e13195. doi: 10.1016/j.heliyon.2023.e13195. eCollection 2023 Feb.

Authors

Zheng Jin¹, Fei Peng², Chao Zhang³, Shuang Tao⁴, Damo Xu^{1

5}, Zhenhua Zhu⁶

Affiliations

¹ Department of Respirology & Allergy, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China.
² Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA.
³ Guangzhou Women and Children's Medical Center, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
⁴ Department of Otorhinolaryngology Head and Neck Surgery, Longgang Central Hospital of Shenzhen, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.
⁵ State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, Guangdong Province, China.
⁶ Department of Orthopaedic Trauma, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong Province, China.

Abstract

Kinesin family member 20A (KIF20A) is a member of the kinesin family. It transports chromosomes during mitosis, plays a key role in cell division. Recently, studies proved that KIF20A was highly expressed in cancer. High expression of KIF20A was correlated with poor overall survival (OS). In this review, we summarized all the cancer that highly expressed KIF20A, described the role of KIF20A in cancer. We also organized phase I and phase II clinical trials of KIF20A peptides vaccine. All results indicated that KIF20A was a promising therapeutic target for multiple cancer.

Keywords: ATP, adenosine triphosphate; BTC, biliary tract cancer; CPC, chromosomal passenger complex; CTL, cytotoxic T lymphocyte; Cancer; Cdk1, cyclin-dependent kinase 1; DLG5, discs large MAGUK scaffold protein 5; EMT, epithelial-mesenchymal transition; Expression; FoxM1, forkhead box protein M1; GC, gastric cancer; GEM, gemcitabine; Gli2, glioma-associated oncogene 2; HLA, human leukocyte antigen; HNMT, head-and-neck malignant tumor; IRF, interferon regulatory factor; JAK, Janus kinase; KIF20A; KIF20A, kinesin family member 20A; LP, long peptide; MHC I, major histocompatibility complex I; MKlp2, mitotic kinesin-like protein 2; Mad2, mitotic arrest deficient 2; OS, overall survival; PBMC, peripheral blood mononuclear cell; Plk1, polo-like kinase 1; Regulating mechanisms; Therapeutic target; circRNA, circular RNA; miRNA, microRNA.

Publication types

Review